{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:14:34Z","timestamp":1791101674187,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T00:00:00Z","timestamp":1296086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold>Hyperuricaemia is a significant factor in a variety of diseases, including gout and cardiovascular diseases. The kidney plays a dominant role in maintaining plasma urate levels through the excretion process. Human renal urate transporter URAT1 is thought to be an essential molecule that mediates the reabsorption of urate on the apical side of the proximal tubule. In this study the pharmacological characteristics and clinical implications of URAT1 were elucidated.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold>Madin\u2013Darby canine kidney (MDCK) cells stably expressing URAT1 (MDCK\u2010URAT1) were established and examined the interactions of URAT1 with various drugs such as benzbromarone and its metabolites including 6\u2010hydroxybenzbromarone, angiotensin\u2010converting enzyme inhibitors, non\u2010steroidal anti\u2010inflammatory drugs and urate transport inhibitors including E3040 and probenecid.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold>MDCK\u2010URAT1 cells exhibited a time\u2010 and dose\u2010dependent increase in urate uptake, with a Km value of 570.7\u2003\u00b5mol\/L. When an URAT1\u2010green fluorescent protein fusion protein construct was expressed in MDCK cells, the protein was sorted mainly to the apical side of the membrane. The drugs except for captoril dose\u2010dependently inhibited urate uptake mediated by URAT1, with half maximal inhibitory concentration (IC<jats:sub>50<\/jats:sub>) values ranging 0.05\u2013716\u2003\u00b5mol\/L.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold>Comparing these IC<jats:sub>50<\/jats:sub>values with intratubular concentrations of unbound drugs in humans, it is thought that URAT1 is a target molecule of uricosuric drugs, including 6\u2010hydroxybenzbromarone, probenecid, indomethacin and salicylate, to inhibit urate reabsorption<jats:italic>in vivo<\/jats:italic>. In addition, a cell line that stably expressing URAT1 could be a useful tool for the development of uricosuric drugs.<\/jats:p>","DOI":"10.1111\/j.1440-1797.2010.01368.x","type":"journal-article","created":{"date-parts":[[2010,7,6]],"date-time":"2010-07-06T23:50:35Z","timestamp":1278460235000},"page":"156-162","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Interactions of urate transporter URAT1 in human kidney with uricosuric drugs"],"prefix":"10.1111","volume":"16","author":[{"given":"HO JUNG","family":"SHIN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHIO","family":"TAKEDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ATSUSHI","family":"ENOMOTO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MASAAKI","family":"FUJIMURA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROKI","family":"MIYAZAKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NAOHIKO","family":"ANZAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HITOSHI","family":"ENDOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"680","volume-title":"The Kidney","author":"Sica DA","year":"2000"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328032781a"},{"key":"e_1_2_6_4_2","first-page":"F797","article-title":"Urate transport in brush\u2010border membrane of human kidney","volume":"266","author":"Roch\u2010Ramel F","year":"1994","journal-title":"Am. J. Physiol."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature742"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.112755"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(02)00187-8"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006030264"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.09339SC"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290161"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<77::AID-BDD154>3.0.CO;2-D"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00626-9"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C800156200"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0090-9556(24)15369-X","article-title":"Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system","volume":"28","author":"Zhang L","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0022-3565(24)36490-0","article-title":"Effects of uricosuric and antiuricosuric agents on urate transport in human brush\u2010border membrane vesicles","volume":"280","author":"Roch\u2010Ramel F","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_16_2","first-page":"682","article-title":"Metabolism study of benzbromarone: In vitro metabolism and pharmacokinetics in healthy volunteers","volume":"53","author":"Oikawa T","year":"2004","journal-title":"J. New. Rem. Clin."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498258909043196"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259309059452"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498258709043998"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(94)80011-1"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80263-9"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2002.02692.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02041396"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90357-C"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02125830"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.94.297"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)21366-0","article-title":"Competitive inhibition of methotrexate accumulation in rabbit kidney slices by nonsteroidal anti\u2010inflammatory drugs","volume":"226","author":"Nierenberg DW","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050725"},{"key":"e_1_2_6_29_2","first-page":"1917","volume-title":"Goodman & Guilman's The Phramacological Basis of Therapeutics","author":"Thummel KE","year":"2001"},{"key":"e_1_2_6_30_2","first-page":"1707","volume-title":"Goodman & Guilman's The Pharmacological Basis of Therapeutics","author":"Benet LZ","year":"1996"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01991.x"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1797.2010.01368.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1797.2010.01368.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T18:36:02Z","timestamp":1740249362000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1797.2010.01368.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1440-1797.2010.01368.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1797.2010.01368.x","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]},"assertion":[{"value":"2011-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}